

Adherium Exhibiting at the ACAAI 2022 Annual Scientific Meeting

Melbourne, Australia – 11 November 2022: Adherium Limited (“Adherium” or “the Company”; ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions is pleased to announce it will be exhibiting and show casing the Hailie® platform at the American College of Allergy, Asthma, and Immunology (ACAAI) 2022 Annual Scientific Meeting on 11-13 November in booth #1146 in Louisville, Kentucky to cultivate new business opportunities.

ACAAI is a professional medical association with over 6,000 asthma, allergist-immunologists and allied health professionals, and has been promoting excellence in patient care for more than 75 years.

At this year’s Annual Scientific Meeting, the College is committed to providing the over 2,000 expected attendees with the best education and show casing the newest technologies applied to clinical areas of asthma, allergy and immunology, as well as ideas for new, more diverse and customised approaches to practice such as remote patient monitoring. The event also offers valuable sessions geared toward effective practice management for doctors and their support teams, including reimbursement billing and coding.

The emergence of remote patient monitoring has created the opportunity for large allergy clinics to develop reimbursable monitoring programs enabled by Adherium’s Hailie® sensor technology and cloud-based data platform for difficult-to-treat and severe asthma patients. By capturing a patient’s inhaler physiological parameters and usage data, Adherium’s new series of devices provide a superior perspective into patient adherence and technique with immediate, real-time feedback thereby allowing patients to improve their quality of life and enabling physicians to enhance patient care.



For new business development and building the Hailie® brand awareness, a selected range of Adherium's Hailie® digital sensors will be on display in the Exhibit Hall of the annual meeting, including the most recently FDA 510(k) cleared device designed for use with the Breo®, Anoro®, Incruse®, Trelegy® and Arnuity® Ellipta® dry powder inhalers (DPIs), for monitoring asthma and COPD medication use.

For more details, please visit: <https://annualmeeting.acaai.org/>

-ENDS-

About Adherium (ASX: ADR)

Adherium is a provider of integrated digital health solutions and a worldwide leader in connected respiratory medical devices, with more than 180,000 sold globally. Adherium's Hailie® platform solution provides clinicians, healthcare providers and patients access to remotely monitor medication usage parameters and adherence, supporting reimbursement for qualifying patient management.

The Hailie® solution includes a suite of integration tools to enable the capture and sharing of health data via mobile and desktop apps, Software Development Kit (SDK) and Application Programming Interface (API) integration tools, and Adherium's own broad range of sensors connected to respiratory medications. Adherium's Hailie® solution is designed to provide visibility to healthcare providers of medication use history to better understand patterns in patient respiratory disease.

Learn more at www.adherium.com

This ASX announcement was approved and authorised for release by the Board of Adherium.

Enquiries: WE Communications
WE-AUAdherium@we-worldwide.com